Medical Advocates
Maraviroc (Selzentry)
 
Journal Citations

General Reports
Pharmacokinetics
Drug/Drug Interactions
 Efficacy





 

  
Maraviroc Main Page Main New/Newsworthy Home Page      
Last Update:  October 06, 2008 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
Price DA, Armour D, de Groot M, et al  
Curr Top Med Chem. 2008;8(13):1140-51.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Maraviroc, risks and benefits: a review of the clinical literature.
Emmelkamp JM, Rockstroh JK.
Expert Opin Drug Saf. 2008 Sep;7(5):559-69.
 Abstract
 
Maraviroc: The First of a New Class of Antiretroviral Agents.
Macarthur RD, Novak RM. 
Clin Infect Dis. 2008 Jun 4.
Abstract

Maraviroc: integration of a new antiretroviral drug class into clinical practice.
Vandekerckhove L, Verhofstede C, Vogelaers D. 
J Antimicrob Chemother. 2008 Apr 9
Abstract

A WEEK IN REVIEW FEATURED REPORT
Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD, Hackman F, Layton G, et al  
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75
 Abstract
 
A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist
maraviroc.
Jacqmin P, McFadyen L, Wade JR. 
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:95-106.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc.
Fadel H, Temesgen Z.
Drugs Today (Barc). 2007 Nov;43(11):749-58.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S. 
Issues Emerg Health Technol. 2007 Dec;(110):1-8.
 Abstract

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection
and AIDS.
Meanwell NA, Kadow JF. 
Curr Opin Investig Drugs. 2007 Aug;8(8):669-81.
 Abstract
 
  Access denied? The status of co-receptor inhibition to counter HIV entry.
Biswas P, Tambussi G, Lazzarin A
Expert Opin Pharmacother. 2007 May;8(7):923-33.
 Abstract
 
Assessing theoretical risk and benefit suggested by genetic association studies of CCR5:
experience in a drug development programme for maraviroc.
Wheeler J, McHale M, Jackson V, Penny M.
Antivir Ther. 2007;12(2):233-45.
 Abstract
 
FULL TEXT ARTICLE
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority
of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a
pretreatment CXCR4-using virus reservoir.
Westby M, Lewis M, Whitcomb J, et al
J Virol. 2006 May;80(10):4909-20.
Paper
 
  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of
chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P, Westby M, Dobbs S, et al
Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32.
Paper
 
  FULL TEXT ARTICLE
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential
treatment for HIV.
Walker DK, Abel S, Comby P, et al
Drug Metab Dispos. 2005 Apr;33(4):587-95.
Abstract
Pharmacokinetics
 
 
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by
maraviroc in healthy subjects and HIV-positive patients.
Rosario MC, Jacqmin P, Dorr P, et al 
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:86-94
 Abstract
 
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic
HIV-infected subjects.
Chan PL, Weatherley B, McFadyen L. 
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:76-85.
 Abstract
 
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of'
maraviroc in healthy volunteers.
Abel S, Jenkins TM, Whitlock LA, et al 
 Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46.
 Abstract
 
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S, Russell D, Taylor-Worth RJ, et al  
Br J Clin Pharmacol. 2008 Apr;65
Abstract
 
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5
antagonist, in healthy volunteers.
Abel S, van der Ryst E, Rosario MC, et al
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:5-18.
 Abstract

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of
maraviroc.
Rosario MC, Poland B, Sullivan J, et al
 J Acquir Immune Defic Syndr. 2006 Jun;42(2):183-91.
 Abstract
Drug/Drug Interactions
 
 
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc
in healthy volunteers.
Abel S, Russell D, Whitlock LA, et al  
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:47-53.
 Abstract
 
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and
ethinyloestradiol/levonorgestrel in healthy volunteers.
Abel S, Russell D, Whitlock LA. et al  
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:19-26.
 Abstract
 
A novel probe drug interaction study to investigate the effect of selected antiretroviral
combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL, Boffito M, Russell D, et al 
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:54-9.
 Abstract
Efficacy
 
 
A WEEK IN REVIEW FEATURED REPORT
Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM, Lalezari J, Goodrich J, et al 
N Engl J Med. 2008 Oct 2;359(14):1429-41.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, et al
 N Engl J Med. 2008 Oct 2;359(14):1442-55.
 Abstract
 
Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a
multi-resistant HIV-infected source person.
Méchai F, Quertainmont Y, Sahali S, et al
J Med Virol. 2007 Nov 26;80(1):9-10
Abstract

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected
with HIV-1.
Fatkenheuer G, Pozniak AL, Johnson MA, et al
Nat Med. 2005 Nov;11(11):1170-2.
Abstract
Adverse Events
 
 
A WEEK IN REVIEW FEATURED REPORT
Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
[No authors listed]
Prescrire Int. 2008 Jun;15(33):98-101.
 Abstract

Maraviroc Main Page Main New/Newsworthy Home Page      

Maraviroc (Selzentry) Journal Citations